October 21, 2014 @ 4:00 pm – 6:00 pm
Anlyan Center at Yale School of Medicine
300 Cedar Street
New Haven, CT 06519
Suggested Donation: $15

This BioHaven session has convened distinguished and experienced panelists to discuss the translation of regenerative medicine technologies into profitable and scalable business models. The field of regenerative medicine has experienced many roadblocks towards commercial success; however, it is currently poised to transition from a purely research-driven focus into commercializable therapies. Given the unique challenges of starting businesses in this space, including complex product designs, regulatory, clinical development and mass production hurdles, as well as safe, reliable distribution of product, our panelists will provide their perspective on challenges they have faced and potential ways to overcome them. This session should provide a unique opportunity for scientists and entrepreneurs to learn from experienced individuals in this rapidly growing space.After panelist presentations and plenty of time for Q & A, appetizers and beverages will be served to bolster your networking conversations.

Susan Froshauer headshotSusan Froshauer, PhD, President and CEO, CURE





Amogh is a fourth year PhD student in biomedical engineering in Dr. Laura    Niklason’s lab and an Advanced GraduateLeadership Fellow at Yale School of Management. Amogh’s work focuses on using pluripotent stem cells for vascular tissue regeneration. Specifically, he is interested in using endothelial cells from pluripotent stem cells for cell therapy applications to ultimately improve therapeutic vascularization in the context of solid organ transplantation. He previously worked at the National Institutes of Health on pre-clinical screening of chemotherapeutics effective in combination with immunotherapy for cancer treatment. He holds a B.S. in biomedical engineering from University of Virginia.



Valerie Horsley, Ph.D.
Valerie Horsely is currently the Maxine F Singer PhD Asst Prof Molecular, Cellular & Developmental Biology at Yale after finishing her postdoctoral work with Elaine Fuchs at Rockefeller University. She is the reciepent of President Obama’s 2012 Early Career Award for Scientist and Engineers. The broad interests of the Horsley Laboratory are to understand tissue organogenesis, homeostasis, and regeneration using skin as a model system to define how epithelial stem cells and other cell types interact to regulate the function of skin cells. Valerie graduated from Furman University with her B.S. and from Emory with her Ph.D.


wei1Mei Wei, PhD 
Mei Wei is a Professor in the Department of Materials Science and Engineering and the Department of Biomedical Engineering, and Associate Dean of the School of Engineering, University of Connecticut. Her research focuses on biomaterials  and tissue engineering. She is a co-founder of a biomedical device company, OrteoPoniX LLC.



Christopher Loose, PhD
Chris currently serves as the Executive Director of the Center for Biomedical and Interventional Technology (CBIT), while hold an appointment as Assistant Professor Adjunct in Urology at Yale. He co-founded Semprus BioSciences with Bob Langer, Institute Professor at MIT, and served as CTO through company acquisition (TFX, $80M) and FDA approval of a vascular catheter with reduced thrombus. He is an Accelerator Executive at CIMIT, a medical device accelerator comprised of 12 former CEO/CTOs that define path for academic research to become fundable by private investors. Chris holds a PhD in Chemical Engineering from the Massachusetts Institute of Technology (MIT).


Kyle Kolaja, PhDKolaja_photo2
Kyle Kolaja is currently Vice President, Business Development at Cellular Dynamics, International, a leading developer of stem cell technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking.  In this role, Dr. Kolaja leverages his 15 years of pharmaceutical experience as a toxicology thought leader to seek and establish novel preclinical and clinical applications of pluripotent stem cells and their derived tissues. Prior to joining CDI, Dr. Kolaja was Leader/Global Head of Predictive Toxicology Screens and Investigative Toxicology at Roche, where he oversaw laboratories in US and Europe that conducted all safety screening assays, provided toxicology support to projects, and applied stem cell derived tissues to safety. Dr. Kolaja has nearly 70 peer-reviewed publications and reviews including 12 on applications of stem cell derived tissues in early safety.